FDA
-
-
-
-
-
-
-
Boundless Bio (BOLD) Provides Business Updates Focused on Key Value Drivers and Reports Second Quarter 2024 Financial Results
-
-
-
-
-
-
-
Audentes Therapeutics Presents New Positive Data from ASPIRO, the Clinical Trial Evaluating AT132 in Patients with X-Linked Myotubular Myopathy (XLMTM), at the 24th International Annual Congress of th
-
-
-
-
-
-
-
Audentes Therapeutics Announces Upcoming Presentations at 22nd Annual Meeting of the American Society of Gene and Cell Therapy Including New Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 in
-
-
-
-
-
-
-
Audentes Therapeutics Reports on Recent Progress and Outlines 2019 Key Priorities
-
-
-
-
-
-
-
RMAT Designation Signals Audentes Therapeutics (BOLD) Could File For Reg Approval Based On Ph 1/2 Data - Mizuho
-
-
-
-
-
-
-
Audentes Therapeutics (BOLD) Announces Continuing Positive Data from First Dose Cohort of ASPIRO
-
-
-
-
-
-
-
Audentes Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

